CNTB (Connect Biopharma Holdings) FCF Margin % : 0.00% (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Connect Biopharma Holdings's Free Cash Flow for the three months ended in Mar. 2025 was $-10.04 Mil. Connect Biopharma Holdings's Revenue for the three months ended in Mar. 2025 was $0.00 Mil. Therefore, Connect Biopharma Holdings's FCF Margin % for the quarter that ended in Mar. 2025 was 0.00%.

As of today, Connect Biopharma Holdings's current FCF Yield % is -26.82%.

The historical rank and industry rank for Connect Biopharma Holdings's FCF Margin % or its related term are showing as below:

CNTB' s FCF Margin % Range Over the Past 10 Years
Min: -93.58 Med: -93.58 Max: -72.25
Current: -72.25

During the past 6 years, the highest FCF Margin % of Connect Biopharma Holdings was -72.25%. The lowest was -93.58%. And the median was -93.58%.

CNTB's FCF Margin % is ranked better than
52.95% of 999 companies
in the Biotechnology industry
Industry Median: -100.31 vs CNTB: -72.25

Connect Biopharma Holdings FCF Margin % Historical Data

The historical data trend for Connect Biopharma Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings FCF Margin % Chart

Connect Biopharma Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-93.58

Connect Biopharma Holdings Quarterly Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Mar24	Jun24	Dec24	Mar25
FCF Margin %	Get a 7-Day Free Trial							-	-	-30.61	-	-

Competitive Comparison of Connect Biopharma Holdings's FCF Margin %

For the Biotechnology subindustry, Connect Biopharma Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Connect Biopharma Holdings's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Connect Biopharma Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Connect Biopharma Holdings's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-24.362	/	26.033
	=	-93.58 %

Connect Biopharma Holdings's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	-10.04	/	0
	=	%

Connect Biopharma Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Connect Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO, CA, USA, 92130

Website

https://www.connectbiopharm.com

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.